The obstructive sleep apnea syndrome (OSAS) is characterized by collapse of the upper airway during sleep, recurring apneas, intermittent hypoxemia and daytime somnolence. OSAS is often associated with obesity, and its prevalence is expected to rise due to the obesity epidemics worldwide. OSAS is associated with increased cardiovascular risk which appears to be normalized by treatment with nasal continuous positive airway pressure (nCPAP) during sleep, suggesting an independent role of OSAS in accelerating atherosclerosis. Insulin resistance (IR) and the metabolic syndrome (MetS) are often found in OSAS patients, but the relative role played by OSAS and obesity is still unclear. Both OSAS and MetS may exert negative synergistic effects on the cardiovascular system through multiple mechanisms (hypoxemia, sleep disruption, activation of the sympathetic nervous system, inflammatory activation). Besides nCPAP treatment, pharmacologic interventions to treat obesity and the MetS could improve cardiovascular prevention in OSAS.

Bonsignore, M.R., Zito, A. (2008). Metabolic aspects of the obstructive sleep apnea syndrome (OSAS) and cardiovascular risk. ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY, 114(4), 255-260 [10.1080/13813450802307451].

Metabolic aspects of the obstructive sleep apnea syndrome (OSAS) and cardiovascular risk

BONSIGNORE, Maria Rosaria;
2008-01-01

Abstract

The obstructive sleep apnea syndrome (OSAS) is characterized by collapse of the upper airway during sleep, recurring apneas, intermittent hypoxemia and daytime somnolence. OSAS is often associated with obesity, and its prevalence is expected to rise due to the obesity epidemics worldwide. OSAS is associated with increased cardiovascular risk which appears to be normalized by treatment with nasal continuous positive airway pressure (nCPAP) during sleep, suggesting an independent role of OSAS in accelerating atherosclerosis. Insulin resistance (IR) and the metabolic syndrome (MetS) are often found in OSAS patients, but the relative role played by OSAS and obesity is still unclear. Both OSAS and MetS may exert negative synergistic effects on the cardiovascular system through multiple mechanisms (hypoxemia, sleep disruption, activation of the sympathetic nervous system, inflammatory activation). Besides nCPAP treatment, pharmacologic interventions to treat obesity and the MetS could improve cardiovascular prevention in OSAS.
2008
Settore MED/10 - Malattie Dell'Apparato Respiratorio
Bonsignore, M.R., Zito, A. (2008). Metabolic aspects of the obstructive sleep apnea syndrome (OSAS) and cardiovascular risk. ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY, 114(4), 255-260 [10.1080/13813450802307451].
File in questo prodotto:
File Dimensione Formato  
APB.pdf

Solo gestori archvio

Dimensione 132.25 kB
Formato Adobe PDF
132.25 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/47059
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 24
  • ???jsp.display-item.citation.isi??? ND
social impact